BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 14, 2026 | Analysis

WuXi Biologics' Hebei Facility Clears US FDA Pre-License Inspection for Commercial Manufacturing

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance ma...

July 13, 2026 | News

Matica Bio Partners with VaxDome to Advance Novel Intranasal Antiviral Vaccine Platform into Clinical Trials

Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotec...

July 08, 2026 | News

The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?

In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...

July 07, 2026 | Analysis

Lonza Expands Commercial ADC Payload-Linker Manufacturing at Visp to Support Growing Oncology Pipeline

Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market Investment...

July 01, 2026 | News

Icosagen Completes €45 Million Expansion to Deliver End-to-End Biologics Development and GMP Manufacturing at a Single Site

Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and man...

July 01, 2026 | News

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires

For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...

June 25, 2026 | Analysis

WuXi Biologics Achieves First GMP Production at Shanghai MFG17, Expanding Global Biologics Manufacturing Capacity

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance f...

June 25, 2026 | News

Pelago Bioscience Acquires RG Discovery to Create Integrated Chemistry-to-Biology Drug Discovery Platform

Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement as...

June 17, 2026 | News

Chime Biologics Expands Manufacturing Capacity With New GMP-2 Facility And AI Powered Megafactory Vision

Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform ...

June 10, 2026 | News

Curocell And ProBio Achieve Korean Milestone With Approval Of Next Generation CAR T Therapy Anbal cel

Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovation Given the accelerating global momentum in CAR-T and gene th...

May 13, 2026 | News

ABEC Expands Process Sciences Capabilities To Accelerate Bioprocess Development And Scale Up

ABEC, a global leader in bioprocess engineering solutions, announced the expansion of its Process Sciences group, expanding its ability to ...

May 08, 2026 | News

VectorBuilder Secures European Patent For MiniVec Plasmid System Advancing Genetic Medicine Development

Small by design, built for the demands of modern genetic medicine across gene therapy, cell therapy, and vaccines VectorBuilder, a global leader in ...

May 06, 2026 | News

Stay Connected